BioCryst Pharmaceuticals grants stock options and RSUs to nine new employees as part of their employment inducement.
Quiver AI Summary
BioCryst Pharmaceuticals, Inc. announced that its compensation committee has granted stock options and restricted stock units (RSUs) to nine new employees, totaling 33,950 stock options and 80,650 RSUs. These grants, which took effect on June 1, 2026, are part of the company's inducement to hire these employees, complying with Nasdaq Listing Rule 5635(c)(4). The options, priced at $8.57 per share, will vest in four equal annual installments starting one year from the grant date, contingent on the employees' continued service. BioCryst specializes in developing treatments for rare diseases, including hereditary angioedema, and has launched ORLADEYO®, a pioneering oral medication for this condition.
Potential Positives
- BioCryst Pharmaceuticals has successfully attracted new talent by granting stock options and restricted stock units to nine newly-hired employees, indicating strong recruitment efforts and investment in human resources.
- The stock options and RSUs are structured to align employee interests with the company's performance, enhancing long-term commitment and potential productivity of the new hires.
- The equity grants comply with Nasdaq Listing Rule 5635(c)(4), demonstrating adherence to regulatory standards and corporate governance practices, which can enhance investor confidence.
- BioCryst continues to develop its innovative pipeline, with a focus on rare diseases, indicating a commitment to addressing unmet medical needs and potential market growth opportunities.
Potential Negatives
- The announcement of stock options and RSUs for newly-hired employees may raise concerns about excessive compensation practices, particularly if tied to talent acquisition rather than performance.
- The granting of shares could dilute existing shareholder value, which may be negatively perceived by current investors.
- The reliance on stock options as an inducement for new hires may suggest challenges in attracting talent or a competitive hiring environment in the biotechnology sector.
FAQ
What stock options and RSUs were granted by BioCryst Pharmaceuticals?
BioCryst granted stock options for 33,950 shares and RSUs for 80,650 shares to nine new employees.
When were the stock options and RSUs granted?
The stock options and RSUs were granted on June 1, 2026.
What is the exercise price for the stock options?
The exercise price for the stock options is $8.57 per share, matching the closing price on the grant date.
How do the stock options and RSUs vest?
They vest in four equal annual installments, starting on the one-year anniversary of the grant date.
What is the focus of BioCryst Pharmaceuticals?
BioCryst focuses on developing and commercializing medicines for hereditary angioedema and other rare diseases.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$BCRX Insider Trading Activity
$BCRX insiders have traded $BCRX stock on the open market 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $BCRX stock by insiders over the last 6 months:
- ALANE P BARNES (Chief Legal Officer) has made 0 purchases and 4 sales selling 255,483 shares for an estimated $2,297,569.
- THERESA HEGGIE sold 49,933 shares for an estimated $504,822
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$BCRX Revenue
$BCRX had revenues of $156.4M in Q1 2026. This is an increase of 7.48% from the same period in the prior year.
You can track BCRX financials on Quiver Quantitative's BCRX stock page.
You can access data on BCRX stock through the Quiver Quantitative API.
$BCRX Hedge Fund Activity
We have seen 184 institutional investors add shares of $BCRX stock to their portfolio, and 152 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- TCG CROSSOVER MANAGEMENT, LLC added 11,020,968 shares (+inf%) to their portfolio in Q1 2026, for an estimated $104,919,615
- JANUS HENDERSON GROUP PLC added 7,310,745 shares (+7807.2%) to their portfolio in Q4 2025, for an estimated $57,023,811
- ALKEON CAPITAL MANAGEMENT LLC removed 5,464,021 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $42,619,363
- VESTAL POINT CAPITAL, LP added 4,775,000 shares (+212.2%) to their portfolio in Q1 2026, for an estimated $45,458,000
- ABERDEEN GROUP PLC added 4,127,077 shares (+451.7%) to their portfolio in Q1 2026, for an estimated $39,289,773
- FRAZIER LIFE SCIENCES MANAGEMENT, L.P. added 4,009,240 shares (+inf%) to their portfolio in Q1 2026, for an estimated $38,167,964
- KYNAM CAPITAL MANAGEMENT, LP removed 3,685,731 shares (-39.4%) from their portfolio in Q1 2026, for an estimated $35,088,159
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$BCRX Analyst Ratings
Wall Street analysts have issued reports on $BCRX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- RBC Capital issued a "Outperform" rating on 01/30/2026
To track analyst ratings and price targets for $BCRX, check out Quiver Quantitative's $BCRX forecast page.
$BCRX Price Targets
Multiple analysts have issued price targets for $BCRX recently. We have seen 5 analysts offer price targets for $BCRX in the last 6 months, with a median target of $21.0.
Here are some recent targets:
- Laura Chico from Wedbush set a target price of $21.0 on 05/07/2026
- Jonathan Wolleben from Citizens set a target price of $28.0 on 05/07/2026
- Serge Belanger from Needham set a target price of $16.0 on 05/06/2026
- Brian Abrahams from RBC Capital set a target price of $13.0 on 01/30/2026
- Andrew S. Fein from HC Wainwright & Co. set a target price of $32.0 on 12/15/2025
Full Release
RESEARCH TRIANGLE PARK, N.C., June 09, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted nine newly-hired employees stock options to purchase an aggregate of 33,950 shares, and restricted stock units (RSUs) covering an aggregate of 80,650 shares, of BioCryst common stock. The options and RSUs were granted as of June 1, 2026, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $8.57 per share, which is equal to the closing price of BioCryst common stock on the grant date. The options and RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee’s continued service with the company. Each stock option has a 10-year term. The options and RSUs are subject to the terms and conditions of BioCryst’s Inducement Equity Incentive Plan and a stock option agreement or restricted stock unit agreement, as applicable, covering the grant.
About BioCryst Pharmaceuticals
BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (“HAE”) and other rare diseases, driven by its deep commitment to improving the lives of people living with these conditions. BioCryst has commercialized ORLADEYO ® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of potential first-in-class or best-in-class oral small-molecule and injectable protein therapeutics for a range of rare diseases. For more information, please visit www.biocryst.com or follow us on LinkedIn .
BCRXW
Contact:
Investors:
[email protected]
Media:
[email protected]
